Developmental pharmacodynamics: drug targets, concentration-effect relationships and impact on drug safety
Year: 2026
Type: article
Abstract: The field of developmental pharmacology is concerned with how the process of growth and maturation bears on drug action and disposition, with a view to applying such knowledge for sound therapy in children. One can see from recent progress in developmental pharmacokinetics (PK) why it is unwise to rely on simple weight-based scaling of an adult dose; shifts in body composition, protein binding, metabolism and elimination render that approach unreliable. Yet these are only part of the picture. Even when a dose achieves the desired plasma level, the outcome in terms of benefit or side effects can be quite another matter if the drug target or the patient's ability to put up with the effect has changed with development (Kearns et al., 2003;van den Anker et al., 2018).Then there is the matter of developmental pharmacodynamics (PD), which addresses age-related structural and functional changes in biological response systems and their implications for toxicity, potency and the therapeutic range (Mulla, 2010). In this context, one must consider the developing patient and the specific therapeutic issue at hand, not merely chronological age. A school-age child on a medication that affects growth, an infant receiving immunosuppression and a newborn with acute brain injury each pose distinct PD challenges. It would be a mistake to attribute any clinical differences in response to receptor ontogeny without considering the interplay of genetic variation, disease and prior treatment (Watanabe et al., 2024).In making the case for a clear separation between the properties of the drug target and those of the biological system that converts target engagement into a clinical result, this review will cover mechanisms, measurement, extrapolation, and safety, along with illustrative examples from therapy. We give particular consideration to neonates and infants, given the difficulty of extrapolation and the speed of their physiological transitions, though developmental PD in older children through puberty is also within scope. Our purpose is to determine what the evidence supports and what remains hypothesis, and to highlight observations that might inform better treatment decisions (Conklin et al., 2019;Smits et al., 2022;Massaro et al., 2025).This is a focused narrative review rather than a systematic review or meta-analysis. We identified the literature through targeted searches of PubMed records, Europe PMC, and publisher websites, using developmental pharmacodynamics and pediatric exposure-response concepts, along with drug-specific searches, supplemented by citation tracing from foundational reviews. No exhaustive retrieval, formal risk-of-bias scoring, or pooled effect estimation was performed. The examples provided in the manuscript are illustrative and cannot establish the prevalence of PD differences across all pediatric medicines.One way to approach a developmental interpretation is to follow the path from the dose given, through target-site exposure and engagement, to the ensuing biological response and ultimately the clinical outcome. At every point in this sequence, age can be a factor. Take plasma drug clearance for instance: if it is reduced, exposure is altered by this PK mechanism. Or consider transporters; they can dictate drug access at the target site, so their developmental impact is a PK matter, even if clinical response varies with age (van den Anker et al., 2018;Smits et al., 2022).Plasma concentrations that are equivalent in total may hide variations in unbound levels, tissue distribution, or active-metabolite exposure. A PD difference might be inferred from a divergent response at similar relevant exposures, but only once other possibilities have been ruled out. On the other hand, a transporter governing neuronal chloride gradients will alter the cell's reaction to receptor activation and is of direct PD concern. It is the protein's function, not whether one calls it an enzyme, receptor, or transporter, that defines its place in the causal chain. Tissue susceptibility and exposure need to be treated as separate entities. Failing to make that distinction can lead to the misrepresentation of pediatric dose or adverse-event data as evidence of changed receptor sensitivity (Mulla, 2010;Conklin et al., 2019).In a concentration-response model, development can affect the curve's steepness, the delay in response, the maximum effect attainable, the baseline, and the concentration needed for halfmaximal effect. The clinical meaning of these shifts varies. For example, needing less of a drug to elicit a biomarker response is not the same as securing a larger therapeutic advantage. And efficacy can be on par while toxicity is not, since the two may stem from entirely different pathways. Any quantitative developmental PD work ought to be explicit about which parameter is changing and what the endpoint signifies (Conklin et al., 2019).Another complication is that disease biology and outcome measures differ with age. The effect of a treatment might be modified because the condition in a child is not the same as in an adult, or because the instrument used to gauge symptoms is picking up on different things. One must also account for maturation, organ dysfunction, genotype, comedication, and prior exposure. The most compelling evidence comes from linking reproducible effects and measured concentrations in the same patient, with developmental covariates set in advance and the findings verifiable in an independent group. Table 1 lays out the principal categories of such evidence and where their interpretation ends.Development can affect many factors, from receptor abundance and subtype distribution to coupling efficiency and downstream signaling. Such mechanisms can alter the response even in the absence of any change in systemic drug exposure. That said, one should not consider receptor expression to be a wholly functional assay on its own. The link between an expression measurement and what is seen clinically may be influenced by receptor reserve, cell composition, or compensatory signaling.As for developmental changes in affinity or the number of receptors, these should only be put forward for a given target if there is direct evidence to back them up; they are part of the framework for pediatric drug action, not a universal rule (Mulla, 2010;Conklin et al., 2019).Then there is the matter of telling normal ontogeny apart from adaptation to disease, which is of particular importance. While placing failing myocardium from adults and children side by side will show age-related variations in disease-associated signaling, it does not, by itself, chart the course of normal receptor maturation, nor can it prove which receptor change drives a treatment's outcome. The most useful mechanistic tissue studies are those done in conjunction with clinical concentration-response data and drug-target engagement. Work on pediatric beta-blockers illustrates the value of receptor biology while also highlighting the pitfalls of drawing inferences from adult heart failure (Miyamoto et al., 2014;Walton and Wagner, 2024).How drugs affect the developing central nervous system depends on several factors: the maturation of receptor subunits and synaptic networks, as well as excitatory and inhibitory signaling. Take the gamma-aminobutyric acid (GABA) type A receptor, for instance; its activation will open an anion channel, but what happens to the membrane potential is in part dictated by the neuronal chloride gradient. In an immature neuron, where there is more chloride accumulation and extrusion is less efficient, the response can be depolarizing. Given that chloride gradients are subject to change according to the brain region, cell type, any injury present, or the stage of development, one would be oversimplifying matters to speak of a single postnatal switch from an excitatory to an inhibitory GABA (Rakhade and Jensen, 2009;Maglalang et al., 2024).Depolarization is not synonymous with net excitation at the network level. In the neonatal mouse neocortex, GABA depolarized immature neurons while exerting inhibitory control over network activity (Kirmse et al., 2015). These preclinical observations argue against treating depolarization as evidence of net excitation, but they do not establish the response to GABAergic antiseizure medicines in human neonates. Mechanistic hypotheses require testing with electrographic outcomes, exposure measurements, and characterization of the underlying brain injury. Developmental differences between species also limit the mapping of postnatal rodent age onto human infant age (Rakhade and Jensen, 2009;Smits et al., 2022).Neonatal immunity reflects adaptation to fetal life and the transition to environmental antigen exposure. Differences in innate recognition, antigen presentation, cytokine responses, and immune regulation affect both protection and inflammation. Describing these responses as simply abnormal obscures their developmental context. Vaccine and immunomodulatory responses may depend on maturation of an entire cellular network rather than the density of one drug receptor. Maternal antibody, antigen experience, infection, and treatment can further influence observed response (Levy, 2007).The immune system's ontogeny can change how we interpret biomarkers. An absolute cell count or cytokine concentration may have a different baseline distribution and clinical meaning in an infant than in an adolescent. Antibody production or cytokine suppression can show biological activity without protecting against disease or reducing infection risk to an acceptable level. Pharmacodynamic studies of immune therapies therefore need age-relevant baseline measurements and a justified connection between the biomarker and the intended clinical outcome (Levy, 2007;Dinh et al., 2020). Ex vivo cyclosporine data, discussed below, provide a specific example of how this question can be investigated (Marshall and Kearns, 1999).A drug-induced change in ventilation, blood pressure, or fluid balance can have different consequences depending on physiological reserve. Prematurity, respiratory disease, cardiac disease, and critical illness may narrow the margin for tolerating such effects. These modifiers should be distinguished from changes in molecular target sensitivity. One might also observe increased drug exposure due to reduced elimination from immature renal function. At the same time, a physiological disturbance can be concerning if the response system cannot compensate. There is no reason these two cannot act in concert (van den Anker and Allegaert, 2012; Massaro et al., 2025).Developmental vulnerability extends beyond the first year of life. Drug effects on linear growth, skeletal maturation, or pubertal development may be clinically significant in older children, even when the same endpoint is less relevant to adults. Toxicity can arise from disruption of a developmental process rather than from an unusually large immediate drug effect. Thus, the exposure window, duration, timing of outcome assessment, and potential for recovery are integral to developmental pharmacodynamics. Longitudinal growth findings associated with inhaled glucocorticoids illustrate this distinction (Kelly et al., 2012a).Sotalol provides an example in which exposure and effect were evaluated together. Läer et al. (2005) analyzed pediatric patients with supraventricular tachycardia using population PK, simulations, and PD models. The PK analysis the analysis and the response analysis In to developmental effects on neonates sensitivity to than older supports a developmental PD to a biomarker rather than every difference to renal The PD and the of on heart limit and these findings should not be to for all neonatal and cyclosporine in blood cell from to drug concentrations to and expression than those from older drug concentrations were in the findings an difference in cellular drug response independent of do not establish the systemic exposure for in an infant or infection for disease, cell composition, and the between the assay and these studies show why direct are and why a PD difference a clinical the of testing mechanisms rather than their therapeutic In a of neonates to and of to in the modified population for to and was associated with more the differences were not significant et al., 2020). The supports efficacy of the in this It does not a or establish of one to chloride with illustrate the of from to therapy. The with and efficacy and in of to all also causal interpretation of et al., 2015). A of neonates in for but efficacy in of treated and of control causal et al., studies should be together. The does not prove that chloride can be and the does not establish a or neonatal Drug access to the transporter of and changes in chloride provides a more direct endpoint than while developmental is needed to determine whether acute suppression to children and et al., 2024).In with et al. of both and in pediatric heart receptor expression was in adult heart Differences also and These findings differences in adaptation to disease and provide a biological reason to question on adults. do not establish the receptor of all children with heart failure or prove that receptor a particular in children and not a significant in its clinical endpoint et al., A is not that is in disease exposure and endpoint affect It also cannot be to a single The tissue and evidence for pediatric studies measurements, and clinically rather than simple of adult efficacy and Wagner, respiratory risk in children reflects rather than a in receptor sensitivity. to and can highlight the of exposure with and respiratory vulnerability (Kelly et al., These are but they do not developmental PD or neonatal receptor review of pediatric case identified renal with active-metabolite toxicity, and as et al., cannot provide or age-related concentration-response a of cardiac patients to no age-related difference in respiratory effects at the same measured concentration et al., that has and a it the that every has a response at equivalent a clinical one must the measured response and developmental PK against such as any respiratory disease on hand, and It is to make a distinction between and respiratory they are separate and separate for they to show how exposure mechanisms can be from physiological and are more in that than as evidence of a particular receptor ontogeny studies show that the developing brain can be to et al. neuronal injury and a exposure in neonatal of these data to children to developmental duration, drug physiological and the of or underlying evidence is more specific than a that remains In the to a single of one infant a outcome equivalent to within the The to the population and it does not or or every et al., The no significant difference a single exposure in children et al., to the in exposure was not to That said, the show to and et al., One must be with such illness and other can the and they do not in prove drugs are the While developmental PD a sound for at and the timing of the evidence is not to all as nor does a single on exposure any of universal findings from studies in a developmental for A pediatric children, of the more with at two and one and et al., clinical do not and the not establish a between pediatric concentration and no clinically difference in to of each of and of was on or about or injury in all treated children et al., The developmental interpretation is a preclinical susceptibility by a clinical and but rather than of an exposure-response effects of inhaled glucocorticoids on linear growth provide another example with a relevant developmental in of the adult was in the than in the the was nor (Kelly et al., illustrates a developmental outcome this effect should be against treatment benefit and for the rather than to every therapeutic or a pediatric was to for acute response, not the response no or medication the first et al., The supports pediatric dose with a clinically failure to at the dose does not prove of the might be to developmental PD by the in dose or exposure between adults and children. Yet such differences are not to receptor sensitivity one also PK, the of the any prior and the of It is for this reason that exposure-response is useful in making those explicit (Conklin et al., In a of is no for a of changes in biology in the pediatric that most drug in the the of drug concentration and effect is most is most done using PD useful measurement target engagement, a downstream PD a clinical and a engagement with the intended biological A PD biomarker a biological response but may not clinical A endpoint for a clinical outcome only when the is for its intended context. These matter when an adult biomarker is into pediatric or a change does not establish et al., on pediatric biomarker and developmental pharmacology et al., et al., we that assay in baseline to the and the to clinically should account for variation, acute or maturation that can change the of The same biomarker may have different implications across developmental changes can be but they do not by disease or We therefore rather than only on adult These are not to be and children, the ability to drug effects varies with development, and on For example, of may be in older children, and physiological observations are needed in endpoint should the measured and a outcome from a et al., illustrates how disease et al. discussed for treatment development, and the addresses and clinical outcome and Drug 2020). For example, in children and in older patients require an adult instrument cannot be across pediatric and must be according to the patient's ability and the and Drug 2020). We whether across where they do not, how measures to the same therapeutic Differences in measurement should not be as evidence that the drug changes with can to human cellular systems and mechanistic as a of in on response and pathways. the of such is on to apart normal maturation or disease from the effects of a It is not to have an blood to in for a cardiac or brain target that is out of nor should one immature in to the of an et al. any from these systems should be against what is seen in and their developmental they dictate benefit comes from applying these to a specific does an immune response with for or is there a at work a given Such is only a first not to be put to immediate clinical In Table we have set out how these of measurement inform the of a pediatric age are for and but they do not biological maturation and should consider age at postnatal and these but distinct of reflects and growth but is not a universal for maturation of receptor In older children, pubertal may be relevant to a particular response should follow a biological and be by the data rather than because they are measurements are for exposure from response can changing and but pediatric which into the model, limit of age effects. and age can render an developmental effect A that the observed data does not a causal maturation mechanism. should exposure and measurement when in independent patients or (Conklin et al., PK drug and may tissue exposure. without a response model, they do not establish receptor ontogeny or the between exposure and drug effect. Mechanistic PD or systems can target and but developmental should explicit The most useful knowledge of maturation with observed pediatric effects and whether change et al., the of the pediatric extrapolation is as a by disease and drug as well as any in or the exposure may be but if evidence from pediatric PD or efficacy studies extrapolation also an explicit when the developmental endpoint has no adult equivalent for developmental the question is which change the dose or the target engagement may about one while clinical outcome disease, changing or may direct pediatric evidence even when systemic PK can be an that every child a independent efficacy can delay access without biological should the the evidence and the pediatric observations that will the (Conklin et al., et al., with the potential to affect or growth are not to by adverse-event In such must be with the of the of and any developmental at risk of The matter two distinct an acute course that is does not speak to developmental outcomes, a point out by work on effects on growth and the developmental PD effects of (Kelly et al., et al., et al., a review of pediatric by et al. of drugs intended for the maximum drug was and of drugs no at one These data about the of they do not the of developmental Longitudinal studies should disease and developmental with that can separate treatment effects from illness evidence also et al. that than of changes for the was not children, or to changes were for of and a risk specific to children. The of that review does not establish the sensitivity of all pediatric data, and can when a developmental by developmental PD is an part of pediatric drug the of evidence across and data for while many examples PK, disease, and physiological Mechanistic is useful for it should not be as a of clinical efficacy or toxicity when the exposure and response observations are follow from this exposure and effect should be unbound drug or when these affect and clinical should be for the developmental population and intended with maturation and disease should and of disruption of growth or These are exposure cannot for an and a biomarker cannot evidence of from the same efficacy or toxicity from should consider whether the in response disease measurement, or reserve. is a response to exposure but it cannot a or developmental interpret an adult therapeutic range within its pediatric evidence rather than it every benefit or The examples of the disease, and developmental stage rather than a rule that patients are more narrative review has several examples with mechanistic or clinical evidence and do not all pediatric therapeutic Tissue and vivo studies have clinical neonatal disease and to effects may not be to maturation These for of and the of rather than a developmental central is that pediatric more than a dose that an adult plasma It justified target-site biological response, clinically and developmental measurement and can make this more efficient, but progress depends on pediatric observations that and where extrapolation is evidence it supports et al., sensitivity of a PD and disease in infant blood cell (Marshall and Kearns, response independent of vivo sensitivity does not a clinical therapeutic adult failing myocardium (Miyamoto et al., adaptation of and tissue cannot establish normal ontogeny or treatment et al., control for receptor or and respiratory studies (Kelly et al., et al., and respiratory require not establish universal neonatal receptor and human studies et al., et al., evidence for a single human exposure duration, and patient limit and et al., et al., findings are within the is not of injury or a (Kelly et al., A developmental outcome depends on the population and PK, pharmacodynamics. categories the type of not a formal The examples are discussed with in and of the was using the biomarker for its assay age-relevant baseline drug and outcome may not clinical the endpoint across child measures to a therapeutic differences for biological adult or evidence disease, response, and pediatric observations that without justified response exposure timing and follow growth, or puberty as effects and by illness or work by et al. et al. and et al. and the for are rather than universal examples et al. and et al. and of the was using
Source: Frontiers in Pharmacology
Authors: Gregory L. Kearns(Conceptualization, Data curation, Writing – original draft, Writing – review & editing), Madeline Belknap(Validation, Writing – original draft, Writing – review & editing), Kate Myers(Validation, Writing – original draft, Writing – review & editing), Colton Slabe(Validation, Writing – original draft, Writing – review & editing)
Institution: Texas Christian University
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236418138
